華伍股份(300095.SZ):董事聶璐璐擬減持不超1020萬股
格隆匯6月3日丨華伍股份(300095.SZ)公佈,公司於2020年6月3日收到董事、副總經理、持股5%以上股東、控股股東一致行動人聶璐璐的《股份減持計劃告知函》。聶璐璐計劃自公告發布之日起15個交易日後的6個月內以集中競價、大宗交易或兩者相結合等方式減持公司股份,減持數量不超過1020萬股(佔公司總股本比例2.7465%)。
其中如以集中競價方式減持的,任意連續九十個自然日內減持股份的總數不超過公司總股本的1%;如以大宗交易方式減持的,任意連續九十個自然日內減持股份的總數不超過公司總股本的2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.